Dynavax ( DVAX ) Q2 Revenue Jumps 29%
Dynavax Technologies ( NASDAQ:DVAX ) , a biotechnology company focused on vaccines, released its results for the second quarter of 2025 on August 7, 2025. The company posted GAAP revenue of $95.4 million, sharply ahead of analyst expectations of $86.7 million, and GAAP diluted earnings per share ...
Dynavax Technologies ( DVAX ) Q2 Earnings and Revenues Beat Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +16.67% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics ( PTGX ) Reports Q2 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Exelixis ( EXEL ) Beats Q2 Earnings Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +15.38% and -1.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting - Dynavax Technologies ( NASDAQ:DVAX )
Dynavax's Strategy is Delivering Significant Long-Term Stockholder Value Dynavax's Nominees Are Vastly Superior to Deep Track's Candidates Across Every Critical Area Follow Recommendations of Proxy Advisory Firms ISS and Egan-Jones and Vote "FOR" All Four of Dynavax's Director Nominees on the ...
Dynavax Comments on Glass Lewis Recommendation - Dynavax Technologies ( NASDAQ:DVAX )
Dynavax is Already Delivering Significant Long Term Stockholder Value Through Execution of Current Strategy Overseen by Board; Deep Track's Inferior Short-Term Plan and Nominees are Not in the Best Interests of All Stockholders
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees - Dynavax Technologies ( NASDAQ:DVAX )
ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials
Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value - Dynavax Technologies ( NASDAQ:DVAX )
Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today
Dynavax Technologies ( DVAX ) Upgraded to Buy: Here's Why
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum - Dynavax Technologies ( NASDAQ:DVAX )
Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Virtus LifeSci Biotech Clinical Trials ETF ( ARCA:BBC ) , Capricor Therapeutics ( NASDAQ:CAPR )
Virtus BBC ETF fell 9.74% to $17.15; SPDR XBI ETF dropped 6.63% to $77.17 on Tuesday. William Blair says Moderna faces increased scrutiny with mRNA vaccines under new CBER leadership. Get prepared for the Fed's next move-live with Matt Maley on Wednesday, May 7 at 6 PM ET. Reserve your free spot ...
Dynavax Technologies ( DVAX ) Reports Q1 Loss, Misses Revenue Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -466.67% and 2.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics ( TGTX ) Lags Q1 Earnings Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -83.33% and 1.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
The U.S. CDC's Advisory Committee recommends the use of GSK's pentavalent Penmenvy vaccine as part of the adolescent meningococcal vaccination schedule.
Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders - Dynavax Technologies ( NASDAQ:DVAX )
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board Refreshment Underscores Deep Track's Value Destructive, Short-Term Focus and Unnecessary Proxy ...
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
Phio Pharmaceuticals stock rallies as safety committee gives green light to advance skin cancer candidate to next dose concentration in phase I study.
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up
Anixa Biosciences stock jumps 13% on new patent grant for its breast cancer vaccine technology in the United States.
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label in lung cancer.
Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study
BAYRY subsidiary Vividion Therapeutics doses the first patient in a phase I study on VVD-159642 to treat advanced solid tumors.
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol
Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates
Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
The FDA approves AZN's sBLA seeking the expanded use of Imfinzi for adult patients with muscle-invasive bladder cancer.
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
Bayer obtains an exclusive worldwide license for MTA-cooperative PRMT5 inhibitor from Suzhou Puhe BioPharma for selective targeting of MTAP-deleted tumors.
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
Pliant stock crashes 89% in three months following setbacks in the mid-stage study of its lead candidate, bexotegrast, for idiopathic pulmonary fibrosis.
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe.
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern. We advise investors to wait for now.
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
The FDA conditionally accepts Plus Therapeutics' new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why
Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.
Why Dynavax Technologies ( DVAX ) Stock Might be a Great Pick
Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
Novartis Reports Updated Positive Data From Phase III SMA Program
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease in adults.
